2022 was the year when the biopharmaceutical company Lipum entered the clinical phase with the drug candidate SOL-116 for the treatment of chronic inflammatory diseases. The phase I study is progressing according to plan and healthy subjects and patients with rheumatoid arthritis will be included in the study. But what will happen in 2023? The company's CEO Einar Pontén provides answers in an interview with BioStock.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/01/lipums-clinical-development-journey-continues-in-2023/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

https://news.cision.com/lipum-ab/r/biostock--lipum-s-clinical-development-journey-continues-in-2023,c3698716

(c) 2023 Cision. All rights reserved., source Press Releases - English